News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Giredestrant ± LHRH analogue fares well in ER+/HER2– early breast cancer
18 May 2026
byAudrey Abella
In the PREcoopERA window-of-opportunity trial, the selective estrogen receptor degrader (SERD) giredestrant shows robust anticancer activity, either alone or in combination with the luteinizing hormone-releasing hormone (LHRH) analogue triptorelin, in premenopausal women with ER+/HER2– operable invasive breast cancer.








